Efficacy of concurrent single-agent chemotherapy using radiotherapy in patients with cervical cancer: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 6, 2015, Pages 8661-8673

  Zhang, Ying ^a   Yang, Zhicheng ^a   Zhou, Yijin ^a   Pan, Jingjing ^a   Liu, Yongyuan ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Concurrent chemotherapy; Meta analysis; Single drug chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; NAVELBINE; NEDAPLATIN; PACLITAXEL;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE EFFECTIVENESS; DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIPOSOMAL DELIVERY; LIVER DYSFUNCTION; META ANALYSIS; NAUSEA AND VOMITING; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84938395428     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. [1] Zhou H, Peng YP, Yu J and Lin ZQ. Interpretation of the clinical practice guidelines for cervical cancer by NCCN (2014). Chin J Pract Obstet and Gyneco 2014; 30: 422-425.
2. [2] Zhang L, Tang J and Zhang JJ. Meta analysis of chemotherapy combination with radiotherapy versus radiotherapy alone in the treatment of locally advanced cervical carcinoma. Chin J Clinicians (Electronic Edition) 2014; 18: 2827-2832.
3. [3] Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL and Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage B cervical carcinoma. N Engl J Med 1999; 340: 1154-1161.
4. [4] Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-1143.
5. [5] Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr and Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-1613.
6. [6] Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL and Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339-1348.
7. [7] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-5812.
8. [8] Petrelli F, De Stefani A, Raspagliesi F, Lorusso D and Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis. Gynecol Oncol 2014; 134: 166-171.
9. [9] Eigel PJ. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol 2006; 3: 248-255.
10. [10] Moher D, Liberati A, Tetzlaff J, Altman DG; and PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
11. [11] Wells GA, Shea B, O’Connell D and Peterson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Health Research Institute Wed Site 2012.
12. [12] Maxwell L, Santesso N, Tugwell PS, Well GA, Judd M and Buchbinder R. Method guidelines for Cochrane Musculoskeletal Group systematic reviews. J Rheumatol 2006; 33: 2304-2311.
13. [13] Deeks J, Higgins JP. Analysis data and undertaking meta-analyses: Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. (Assessed on July 15, 2011 at http://www.cochrane-handbook.org).
14. [14] Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
15. [15] Mantel N and Haenszel E. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
16. [16] Egger M, Davey SG, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
17. [17] Wang HR, Yu CH, Zhu WG and Li T. Comparison of the effect of nedaplatin and cisplatin in the concurrent chemoradiotherapy of cervical cancer. Chin J Pract Obstet and Gyneco 2011; 27: 771-774.
18. [18] Cheng XW, Yang YX and Yu XY. A comparative study of concurrent chemo- radiotherapy with cisplatin versus nedaplatin for patients with middle-advanced stage uterine cervical cancer. Chin J Tumor 2011; 31: 662-664.
19. [19] Lou PR, Tao QS, Guo JX, Yu QB, Dong YE, Wang YH, Xu ZY and Yuan ZG. Clinical study of concurrent cisplatin or nedaplatin-based chemoradiation for locally advanced cervical cancer. J Chin Oncol 2011; 17: 93-96.
20. [20] Wang CX, Lv HQ, Zhu SM, Zhang FQ and Shang CJ. Comparison of the clinical efficacy between nedaplatin and cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical carcinoma. Anti-tumor Pharm 2014; 4: 290-293.
21. [21] Li L. Evaluation of curative effect of nedaplatin concurrent chemoradiotherapy in the treatment of 48 cases of cervical cancer. Chin J Med Front 2014; 6: 74-76.
22. [22] Jiang L, Hao Q and Wang HY. Curative effect of three chemotherapy programs in concurrent with radiotherapy on medium and advanced stage cervical cancer. Chin J Pract Obstet Gyneco 2009; 25: 293-295.
23. [23] Li QF, Jin GW, Bai XJ and Jiang CH. Effect of cisplatin and docetaxel concurrent chemotherapy and radiotherapy in local advanced cervical cancer. Modern Oncol 2011; 19: 1827-1830.
24. [24] Geara FB, Shamseddine A, Khalil A, Abboud M, Charafeddine M and Seoud M. A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. Radiat Oncol 2010; 23: 84.
25. [25] Wan YH, Zhang ZC, Li YX, Li X, Wang XL and Li SW. Curative effect of cisplatin or paclitaxel in concurrent chemoradiotherapy for cervical cancer: a report of 58 cases. J Chin Tradit Chin Med Inform 2011; 3: 162.
26. [26] Narayanan V, Bista B and Sharma S. External beam therapy in a four-field box technique with paclitaxel versus a two-field technique with cisplatin in locally advanced carcinoma cervix: a phase II monocentric trial. ISRN Oncol 2012; 2012: 390193.
27. [27] Nagai N, Oshita T, Murakami J, Shigemasa K, Hirokawa Y and Ohama K. Radiotherapy combined with transcatheter arterial infusion of cisplatin versus oral fluoropyrimidine anticancer agent for locally advanced carcinoma of the uterine cervix: a prospective follow-up study. Oncol Rep 2001; 8: 119-125.
28. [28] Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, Monk BJ and O'Connor DM. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol 2005; 23: 8289-8295.
29. [29] Xin SB, Lin BH, Lin SF and Li HJ. Comparison of the effect between weekly paclitaxel liposome and weekly cisplatin in concurrent radiotherapy in advanced cervical cancer. J Guangdong Med 2014; 35: 761-763.
30. [30] Coronel JA, Cetina Ldel C, Cantú D, Cerezo O, Hernández CS, Rivera L, Chacón AP and Duenas-Gonzalez A. A randomized comparison of cisplatin and oral vinorelbine as radiosensitizers in aged or comorbid locally advanced cervical cancer patients. Int J Gynecol Cancer 2013; 23: 884-889.
31. [31] Wang HJ and Shu CR. Irinotecan combined with radiotherapy for locally advanced cervical carcinoma. J Nanchang Univ (Med Sci) 2012; 52: 52-57.
32. [32] Perez CZ, Grigsby PW and Chao CK. Chemotherapy and irradiation in locally advanced squamous cell carcinoma of the uterne cervix: A review. Semin Radiat Oncol 1997: 7 Suppl 2: 45-65.
33. [33] Fu KK. Biological basis for the interactions of chemotherapeutic agents and radiation therapy. Cancer 1985; 55 Suppl: 2123-2130.
34. [34] Lu JL and Yang F. Clinical pharmacokinetic study of cisplatin in enhancing cervical cancer radiosenstivity. J South Med Univ 2006; 26: 1170-1172.
35. [35] Kim YS, Shin SS, Choi EK, Kim JH, Ahn SD, Lee SW, Park HJ, Kim YT, Mok JE and Nam JH. A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer. Cancer Res Treat 2005; 37: 37-43.
36. [36] Kim YS, Shin SS, Nam JH, Kim YT, Kim YM, Kim JH and Choi EK. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108: 195-200.
37. [37] McQuellon RP, Thaler HT, Cella D and Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol 2006; 101: 296-304.
38. [38] Sehouli J, Runnebaum B, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W and Kuemmel S. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO intergroup study. Ann Oncol 2012; 23: 2259-2264.
39. [39] Hashemi FA, Akbari EH, Kalaghchi B and Esmati E. Concurrent chemoradiation with weekly gemcitabine and cisplatin for locally advanced cervical cancer. Asian Pac J Cancer Prev 2013; 14: 5385-5389.